These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 29495966)

  • 21. [Haploidentical hematopoietic stem cell transplantation: Guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)].
    Nguyen S; Chalandon Y; Lemarie C; Simon S; Masson D; Dhedin N; Suarez F; Renaud B; Charbonnier A; Yafour N; François S; Duléry R; Blaise D; Yakoub-Agha I; Rubio MT
    Bull Cancer; 2016 Nov; 103(11S):S229-S242. PubMed ID: 27842860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
    Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
    Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia.
    Chen Q; Zhao X; Fu HX; Chen YH; Zhang YY; Wang JZ; Wang Y; Yan CH; Wang FR; Mo XD; Han W; Chen H; Chang YJ; Xu LP; Liu KY; Huang XJ; Zhang XH
    Ann Hematol; 2020 Jul; 99(7):1643-1653. PubMed ID: 32458063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for T lymphoblastic leukemia/lymphoma].
    Luo L; Jiao Y; Yang P; Li Y; Huang WY; Ke XY; Zou DH; Jing HM
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):388-394. PubMed ID: 37550188
    [No Abstract]   [Full Text] [Related]  

  • 28. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
    Czyz A; Nagler A
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT).
    Aljurf M; Nassar A; Hamidieh AA; Elhaddad A; Hamladji RM; Bazarbachi A; Ibrahim A; Ben Othman T; Abdel-Rahman F; Alseraihy A; Fahmy O; Hussein AA; Alabdulaaly A; Adil S; Alkindi SS; Bayoumy M; Dennison D; Bekadja MA; Redhouane AN; Rasheed W; AlSagheir A; Alsudairy R; Ladeb S; Benchekroun S; Ramzi M; Ahmed P; ElSolh H; Ahmed SO; Hussain F; Ghavamzadeh A
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):167-75. PubMed ID: 26452331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of second transplantation with T-cell-replete haploidentical graft using low-dose anti-thymocyte globulin on long-term overall survival in pediatric patients with relapse of leukemia after first allogeneic transplantation.
    Kobayashi S; Sano H; Mochizuki K; Ohara Y; Takahashi N; Kudo S; Ikeda K; Ohto H; Kikuta A
    Int J Hematol; 2022 Mar; 115(3):414-423. PubMed ID: 34822127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Fludarabine-based increased-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia].
    Sun C; Lin X; Huang Y; Song C; Tao Y; Tu S; Fang J; Chen T; Sun C; Wu B
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):221-4. PubMed ID: 24666488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
    Chang YJ; Wang Y; Mo XD; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Chen Y; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Cancer; 2017 Aug; 123(15):2881-2892. PubMed ID: 28301690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes].
    Gournay V; Robin M
    Bull Cancer; 2023 Nov; 110(11):1168-1175. PubMed ID: 37516649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study.
    Gao L; Yang L; Zhou S; Zhu W; Han Y; Chen S; Xue S; Wang Y; Qiu H; Wu D; Wu X
    Stem Cell Res Ther; 2024 Jan; 15(1):24. PubMed ID: 38282037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016.
    Yanir AD; Martinez CA; Sasa G; Leung K; Gottschalk S; Omer B; Ahmed N; Hegde M; Eunji J; Liu H; Heslop HE; Brenner MK; Krance RA; Naik S
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1424-1431. PubMed ID: 29550628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of allogeneic hematopoietic stem cell transplantation in treatment of childhood myelogenous leukemia: the observation of 24 cases].
    Sun Y; Sun RJ; Wei ZJ; Xiao J; Zhang YC; Gao YQ; Zhu HL
    Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):813-6. PubMed ID: 23302609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
    Hwang YY; Mohty M; Chim CS
    Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how.
    Magenau J; Couriel DR
    Curr Oncol Rep; 2013 Oct; 15(5):436-44. PubMed ID: 23959811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
    Yoshimi A; Strahm B; Baumann I; Furlan I; Schwarz S; Teigler-Schlegel A; Walther JU; Schlegelberger B; Göhring G; Nöllke P; Führer M; Niemeyer CM
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):425-9. PubMed ID: 24316460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.